Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

Pancreatic cancer survival has finally doubled in a decade to 13 percent, a fragile but real sign that years of slow, methodical progress are beginning to add up. November is Pancreatic Cancer ...

Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with ...

Stage 2 endometrial cancer spreads to the cervical stroma but remains within the uterus and cervix, requiring precise staging and diagnosis. Treatment typically involves surgery, possibly a radical ...

Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...

Computational tool improves recombinant virus design efficiency and yield.This innovative in-house development is a key component of Transgene’s ...

"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The MarketWatch News Department was not involved in the creation of this content.-- Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receivi ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Persistent depression during adjuvant cancer therapy increases treatment toxicity and significantly reduces quality of life, ...